Incentives intended to stimulate the development of more treatments for rare diseases are being exploited to boost the profits of pharmaceutical companies, new research led by Bangor University shows. Company profits Researchers found that companies which market drugs for rare diseases (known as orphan drugs) are 5 times more profitable and have up to 15%…